Impersonal research, traced to filings. An evidence-first read of whether Repligen's move up the value chain is real, well-stewarded, and still underappreciated — the same for every reader, from SEC EDGAR 10-K + 8-K filings. This is not personalized advice or a recommendation to any specific person. As of 24 Jul 2026. Disclosures.
How it scores
Seven dimensions, 0–5 — the baseline everyone has (28%) plus the revealed-behaviour Analysis Bridge (72%). The method →
Baseline
Analysis Bridge
The evidence, dimension by dimension
Execution (do-side)
4/5Clean, verifiable execution turning the destock corner: FY2025 revenue +16.4% with growth across all four franchises and all three regions, gross margin restored to 52.3% (from 43.3%), return to GAAP net income ($48.9M vs $25.5M loss), Q4 beat the high end of guidance, $117.4M operating cash flow. Deducts from 5 because 2024's -5.5% OPM / net loss and heavy reliance on tuck-in M&A (15 deals) to sustain franchise growth show the model still amplifies the demand cycle.
Say/do credibility
4/5Say/do is now favorable: after cutting guidance repeatedly through the 2023-24 destock, management set conservative recovery guides and then BEAT them (Q4 2025 'exceeded the high end of our October revenue and adjusted operating income guidance'), and delivered the promised return to double-digit organic growth + margin expansion. Weighs down one notch for the 2024 Item 4.02 restatement (a revenue-recognition-timing miss on originally reported statements) — contained (timing only, no fraud, no cash impact) but a genuine say/do blemish that keeps this off a 5.
Strategy — IP & partnerships
5/5Textbook up-the-value-chain razor-blade franchise: majority of revenue from proprietary single-use consumables spec-in to GMP biologics processes (high switching costs), 250+ granted + 150+ pending patents across filtration/chromatography/analytics/proteins, and an explicit, executing shift from point products to integrated multi-franchise solutions with vertical integration (ProConnex flowpaths) and in-line analytics. IP + closed-system lock-in + 40-yr installed base is a durable structural moat, not a price-taker position.
Governance & stewardship
3/5Solid balance sheet ($767.6M liquidity, low-coupon convert, no off-balance-sheet vehicles) and orderly CEO succession (founder-era CEO to Executive Chair; Olivier Loeillot as President/CEO). Held back to a 3 by the Sep-2024 Item 4.02 restatement (a revenue-recognition control/judgment lapse on a COVID cancellation payment) and by a large, contingent-consideration-laden serial-acquisition model (15 deals, goodwill/intangible heavy) that raises integration and estimate risk. No fraud/misconduct found.
Margins over the cycle
Operating margin and return on capital across the last decade of SEC filings. A structural climb up the value chain holds its gains through the down-cycle; a commodity name gives them back. Structural vs cyclical →
From SEC EDGAR XBRL.
The say/do credibility ledger
What management promised, versus what the filings show they delivered — the single largest weight in the read.
| Promise | When | Status | What the filings show |
|---|---|---|---|
| Q4 2025 revenue and adjusted operating income at least in line with the October 2025 guidance | 2025-10-28 (Q3 2025 earnings 8-K) | Delivered | Q4 2025 revenue was $198M (+18% reported / +14% organic); CEO stated the company 'exceeded the high end of our October revenue and adjusted operating income guidance.' Beat, not miss. 8-K 2026-02-24 ex-99.1 press release (CEO quote; Q4/FY2025 results) |
| Return to double-digit organic growth and margin expansion as the bioprocessing destock unwinds (recovery from 2023-24 downcycle) | 2024-2025 recovery-year guidance (post-destock) | Delivered | FY2025 revenue $738.3M, +16.4% (16% organic non-COVID), growth 'widespread across our portfolio' with 15.7% NA / 16.0% EU / 19.3% APAC; gross margin recovered to 52.3% from 43.3%; returned to GAAP net income $48.9M from a $25.5M net loss in 2024. OPM back to 7.5% GAAP (adj op margin materially higher) from -5.5%. 10-K FY2025, Item 7 MD&A — 'Revenues' / 'Cost of goods sold'; baseline fundamentals FY2024-25 |
| Full year 2026 revenue $810M-$840M (10-14% reported, 9-13% organic) with ~150 bps adjusted operating margin expansion | 2026-02-24 (FY2025 earnings 8-K) | Too early | Guidance issued for FY2026; not yet reportable. Track record into this guide is a beat (Q4 exceeded high end), which raises its weight. 8-K 2026-02-24 ex-99.1 press release — '2026 Financial Guidance' |
| New-modality / Proteins and Analytics franchises would become growth engines beyond legacy mAb filtration | Multi-year strategic framing (10-K Business; earnings commentary) | In progress | In 2025 Proteins grew to $97.4M (from $74.4M, +31%), Process Analytics to $81.2M (from $59.3M, +37%, incl. 908 Devices $9.3M); CEO cited Q4 growth 'led by Analytics and Proteins.' Diversification beyond filtration is materially delivering, though acquisition-aided. 10-K FY2025, Item 7 MD&A — product-revenue franchise table; 8-K 2026-02-24 CEO quote |
| Prior-period (2023-H1 2024) financial statements were reliable as originally reported | Original 2023/2024 filings | Missed | On 2024-09-12 the Audit Committee concluded the timing of revenue recognition on a $17.3M COVID cancellation payment was misapplied under ASC 606, requiring restatement of Q1-2023 through Q2-2024 and FY2023. Restatement changed timing only, not total revenue or cash, and 'did not result from any override of controls, misconduct, or fraud.' A controls/judgment miss, but contained and explained. 8-K 2024-09-12, Item 4.02(a) |
Triangulation chain
A real migration lights up all five: stated → approved → funded → permitted → protected. An announced-only one stalls early.
Stated strategy is to move up the value chain from selling individual products toward integrated, spec-in bioprocessing solutions across four franchises (Filtration, Chromatography, Process Analytics, Proteins) that support entire unit operations upstream+downstream, with the majority of revenue from single-use consumables. 'Our commercial approach is shifting from selling individual products to offering our broad portfolio to customers with integrated solutions that can support entire unit operations... and in-line advanced analytics.' (10-K FY2025, Item 1 Business — 'Our Products' / 'Shifting to Integrated Solutions')
Board-level capital allocation is executing: completed the 908 Devices PAT Portfolio acquisition (Mar 2025) and Tantti (Dec 2024) to deepen Process Analytics and chromatography; management states 2026 opex will increase to expand the bioprocessing business and continues to invest in R&D (R&D +25.4% in 2025) and IP portfolio. (10-K FY2025, Item 7 MD&A — '2025 Acquisition' and 'Capital Requirements')
$767.6M cash, cash equivalents and marketable securities at 12/31/2025; $600M 1.00% Convertible Senior Notes due 2028 (effective rate 4.39%); operating cash flow $117.4M in 2025. Management: 'current cash balances and future cash flow from operations are adequate to meet our cash needs for at least the next 24 months.' Fully funded organic + tuck-in M&A program. (10-K FY2025, Item 7 MD&A — 'Liquidity and Capital Resources')
Operates 19 manufacturing sites (US + Estonia, France, Germany, Ireland, Netherlands, Sweden, Taiwan). Products are cGMP-compliant and validated/spec-in to customers' regulated biologics manufacturing processes (KrosFlo RS systems 'cGMP compliance built into every system'). No adverse regulatory/site issues disclosed; no intangible impairments. (10-K FY2025, Item 1 Business — 'Manufacturing' and 'Our Franchises & Products')
Own or hold exclusive rights to 250+ active patent grants and 150+ pending applications across US/EU/China/India/Japan/Korea etc., covering ATF, TFDF, TFF/HF/FS systems, membranes, mixers, flow paths and single-use tech. Deep switching costs: closed/single-use consumables validated into GMP processes, plus vertical integration of fluid-management components into proprietary ProConnex flowpaths. Classic razor-blade franchise. (10-K FY2025, Item 1 Business — 'Intellectual Property' (250+ patents / 150+ pending))
Catalysts
- Bioprocessing destock cycle inflection — return to double-digit organic order growth ('continued momentum in orders') · 2026-02-24
Confirms the downcycle has turned; recovering consumables pull-through drives operating leverage on the razor-blade base.
- Tariff / trade-policy risk on cross-border supply and delivery (Trump-administration tariffs monitored) · 2026-02-26
19 global manufacturing sites and cross-border shipping expose gross margin to tariffs, export duties (already higher in 2025) and FX.
- Next-generation TFDF and ATF filtration patent filings; 908 Devices PAT and Metenova mixing IP integration · 2025-2026
Extends the protected moat into higher-value analytics and fluid-management, reinforcing spec-in and integrated-solution pricing.
Risk flags
- governance_flag
Sep-2024 Item 4.02 non-reliance/restatement of Q1-2023 through Q2-2024 for revenue-recognition timing on a COVID cancellation payment. Contained (timing only, no total-revenue/cash impact, no fraud or control override found), but a real credibility blemish already reflected in E=4 and G=3.
Sources
Bridged from SEC EDGAR 10-K + 8-K filings, latest 10-K filed 26 Feb 2026. Read the 10-K on SEC EDGAR → Provenance: agent-grounded-fulltext. Financials from SEC EDGAR XBRL; price from public market data.